Skip to content
Catalyst

PapersPMID:42337792

Meta-analysis of the effects of ginger supplementation on glycemic control, blood pressure and lipid profile in patients with type 2 diabetes.

Systematic reviews2026The record ↗

findings
8
compound
1
endpoints
8
no difference found
4
PMID:42337792
  1. Finding, moderate evidencelowersSystolic blood pressure
  2. Finding, moderate evidencelowersFasting blood glucose
  3. Finding, moderate evidencelowersGlycated haemoglobin (HbA1c)
  4. Finding, moderate evidenceraisesHDL cholesterol
  5. Finding, moderate evidenceno difference foundLDL cholesterol
  6. Finding, moderate evidenceno difference foundDiastolic blood pressure
  7. Finding, moderate evidenceno difference foundTotal cholesterol (TC)
  8. Finding, moderate evidenceno difference foundBody mass index
Study, every finding
meta-analysis
Dose studied, every finding
1200 to 3000 mg/day, 8 to 12 weeks across trials
  • “Pooling data from 4 clinical trials, the model indicated that ginger significantly reduced systolic blood pressure (MD = −1.62 mmHg, 95% CI (−3.01, −0.24), I2 = 6.09%, τ2 = 0.44, and Cochran’s Q: 3.29), but not diastolic blood pressure (MD = −2.41 mmHg, 95% CI (−5.45, 0.64), I2 = 76.40%, τ2 = 6.07, and Cochran’s Q: 12.71).”
    Effect
    −1.62 mean difference, 95% CI −3.01 to −0.24
    Population
    Patients with type 2 diabetes in placebo-controlled randomized trials of ginger (pooled from 4 trials)
  • “The model indicated that ginger significantly decreased FBS (MD = −16.27 mg/dL, 95% CI (−25.75, −6.80), I2 = 86.39%, τ2 = 158.79, and Cochran’s Q: 66.11), HbA1c (MD = −0.41%, 95% CI (−0.63, −0.20), I2 = 92.09%, τ2 = 0.06, and Cochran’s Q: 113.8), but its effects on HOMAIR did not reach the threshold of statistical significance (MD = −0.37%, 95% CI (−0.78, 0.03), I2 = 76.35%, τ2 = 0.13, and Cochran’s Q: 21.14).”
    • Effect
      −16.27 mean difference, 95% CI −25.75 to −6.8
      Population
      Patients with type 2 diabetes in placebo-controlled randomized trials of ginger (13 trials in the review)
    • Effect
      −0.41 mean difference, 95% CI −0.63 to −0.2
      Population
      Patients with type 2 diabetes in placebo-controlled randomized trials of ginger (13 trials in the review)
  • “Regarding lipid profile, ginger significantly decreased triglyceride level (MD = −17.10 mg/dL, 95% CI (−31.13, −3.07), I2 = 81.61%, τ2 = 334.97, and Cochran’s Q: 48.94) and increased HDL-C level (MD = 2.13 mg/dL, 95% CI (0.44, 3.82), I2 = 85.72%, τ2 = 4.35, and Cochran’s Q: 70.03).”
    Effect
    2.13 mean difference, 95% CI 0.44 to 3.82
    Population
    Patients with type 2 diabetes in placebo-controlled randomized trials of ginger (13 trials in the review)

What did not

  • “However, treatment with ginger did not change total cholesterol level (MD = −4.78 mg/dL, 95% CI (−15.27, 5.70), I2 = 92.45%, τ2 = 208.75, and Cochran’s Q: 119.21) and LDL-C level (MD = −5.36 mg/dL, 95% CI (−12.37, 1.65), I2 = 90.93%, τ2 = 99.72, and Cochran’s Q: 110.31).”
    • Effect
      −5.36 mean difference, 95% CI −12.37 to 1.65
      Population
      Patients with type 2 diabetes in placebo-controlled randomized trials of ginger (13 trials in the review)
    • Effect
      −4.78 mean difference, 95% CI −15.27 to 5.7
      Population
      Patients with type 2 diabetes in placebo-controlled randomized trials of ginger (13 trials in the review)
  • Effect
    −2.41 mean difference, 95% CI −5.45 to 0.64
    Population
    Patients with type 2 diabetes in placebo-controlled randomized trials of ginger (pooled from 4 trials)

    Same sentence as the finding on systolic blood pressure

  • “Pooling data from 8 studies, the random-effects model showed that the beneficial effects of ginger on BMI did not meet the threshold of statistical significance (MD = −0.25 kg/m2, 95% CI (−0.52, 0.03), I2 = 83.05%, τ2 = 0.08, and Cochran’s Q: 41.31).”
    Effect
    −0.25 mean difference, 95% CI −0.52 to 0.03
    Population
    Patients with type 2 diabetes in placebo-controlled randomized trials of ginger (pooled from 8 studies)

Study record

Design
meta-analysis
Species
human
Population
Patients with type 2 diabetes
Participants
not reported
Comparator
placebo
Duration
not reported
Endpoints measured
10